Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9512107 | BRISTOL MYERS SQUIBB | Therapeutically active compositions and their methods of use |
Jan, 2033
(8 years from now) | |
US10093654 | BRISTOL MYERS SQUIBB | Therapeutically active compounds and their methods of use |
Aug, 2034
(10 years from now) | |
US9738625 | BRISTOL MYERS SQUIBB | Therapeutically active compounds and their methods of use |
Aug, 2034
(10 years from now) | |
US9732062 | BRISTOL MYERS SQUIBB | Therapeutically active compounds and their methods of use |
Sep, 2034
(10 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10610125 | BRISTOL MYERS SQUIBB | Methods and compositions for cell-proliferation-related disorders |
Jun, 2030
(6 years from now) | |
US10294215 | BRISTOL MYERS SQUIBB | Therapeutically active compounds and their methods of use |
Jan, 2033
(8 years from now) |
Idhifa is owned by Bristol Myers Squibb.
Idhifa contains Enasidenib Mesylate.
Idhifa has a total of 6 drug patents out of which 0 drug patents have expired.
Idhifa was authorised for market use on 01 August, 2017.
Idhifa is available in tablet;oral dosage forms.
Idhifa can be used as treatment of relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation.
Drug patent challenges can be filed against Idhifa from 01 August, 2021.
The generics of Idhifa are possible to be released after 16 September, 2034.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE) | Aug 01, 2024 |
New Chemical Entity Exclusivity(NCE) | Aug 01, 2022 |
Orphan Drug Exclusivity(ODE-151) | Aug 01, 2024 |
Drugs and Companies using ENASIDENIB MESYLATE ingredient
NCE-1 date: 01 August, 2021
Market Authorisation Date: 01 August, 2017
Treatment: Treatment of relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation
Dosage: TABLET;ORAL